Ptc Therapeutics, INC Form 4 insider transactions

PTC Therapeutics' Chief Business Officer, Eric Pauwels, reported multiple sales of common stock totaling 7,348 shares in early January 2026.

PTC Therapeutics CEO Matthew B. Klein sold 2,514 shares of common stock to cover tax obligations related to RSU vesting.

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold 866 shares of common stock at $76.45 per share to cover tax withholding obligations related to RSU vesting.

A PTC Therapeutics Executive VP and CLO sold common stock totaling 6,347 shares across multiple transactions in early January 2026, primarily under a 10b5-1 plan.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold shares to cover tax liabilities from RSU vesting.

PTC Therapeutics' SVP, Chief Accounting Officer, Christine Marie Utter, sold shares to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,139 shares of common stock at $76.95 per share to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics CEO Matthew B. Klein sold 8,165 shares of common stock in early January 2026 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold shares of common stock on January 6 and 7, 2026, to cover tax withholding obligations related to RSU vesting.

Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, reported multiple stock transactions, including option exercises and sales, primarily for tax withholding and under a 10b5-1 plan.

A PTC Therapeutics officer sold shares to cover tax withholding obligations related to vested restricted stock units.

PTC Therapeutics Director Mary L. Smith acquired 4,000 restricted stock units and 3,475 stock options on January 2, 2026.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, was granted 18,020 restricted stock units and options to purchase 43,750 shares of common stock.

Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, received significant equity grants including restricted stock units and stock options.

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, was granted 18,750 restricted stock units and options for 46,875 shares of common stock.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, was granted 20,000 restricted stock units and options to purchase 50,000 shares of common stock.

PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, reported the acquisition of restricted stock units and stock options, alongside the exercise and sale of common stock, all under a Rule 10b5-1 plan.

PTC Therapeutics Director Emma Reeve reported recent acquisitions of restricted stock units and stock options, alongside a sale of common stock.

PTC Therapeutics Director Jerome B. Zeldis was granted 4,000 restricted stock units and 3,475 stock options on January 2, 2026.

PTC Therapeutics Director Alethia Young was granted restricted stock units and stock options, aligning her interests with shareholders.

PTC Therapeutics Director David P. Southwell was granted 4,000 restricted stock units and 3,475 stock options under a pre-arranged plan.

PTC Therapeutics Director Stephanie Okey was granted 4,000 restricted stock units and 3,475 stock options, effective January 2, 2026.

PTC Therapeutics Director Allan Steven Jacobson acquired 4,000 restricted stock units and 3,475 stock options, increasing his beneficial ownership.

PTC Therapeutics Director Michael Schmertzler received 8,000 restricted stock units and 6,950 stock options, vesting over one year.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, was granted 20,000 restricted stock units and 50,000 stock options on January 2, 2026.

PTC Therapeutics CEO Matthew B. Klein received 63,000 restricted stock units and 157,500 stock options as part of his compensation package.

PTC Therapeutics Director Glenn Steele Jr. exercised options and sold shares under a 10b5-1 plan, while also receiving new restricted stock units and stock options.

PTC Therapeutics CEO Matthew B. Klein sold 8,089 shares of common stock at $76.64 per share to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, executed pre-planned transactions, exercising stock options and selling an equivalent number of common shares.